Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials

Fig. 2

Sensitivity analysis. Overall survival† by treatment in the normal weight (a), overweight (b), and obese (c) cohort, with chemoimmunotherapy treatment effect estimates†† by BMI category (d)

†Kaplan-Meier product limit estimates were derived from the pooled cohort of two RCTs. Blue: chemoimmunotherapy; Red: chemotherapy

††Forest plot estimates (chemoimmunotherapy versus chemotherapy) were derived from stratified (by RCT) Cox proportional hazards regression models with a BMI-by-treatment interaction term

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us